| IVACC Stock | | | SEK 2.60 0.06 2.36% |
CEO
Mr. JanIngmar Flock serves as Chief Scientific Officer at Intervacc AB. He was also Chief Executive Officer of the Company until December 13, 2018. He no longer serves as Director of the Company effective as of June 14, 2018. He is Professor at the Karolinska Institute, Department of Microbiology, Tumor and Cell Biology and holds Ph.D. in Medicine, Karolinska Institute, 1978. since 2018.
| Tenure | 6 years |
| Professional Marks | Ph.D |
| Phone | 46 8 12 01 06 00 |
| Web | https://www.intervacc.se |
Intervacc Management Efficiency
The company has return on total asset
(ROA) of
(0.0991) % which means that it has lost $0.0991 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
(0.1689) %, meaning that it generated substantial loss on money invested by shareholders. Intervacc's management efficiency ratios could be used to measure how well Intervacc manages its routine affairs as well as how well it operates its assets and liabilities.
Intervacc AB has accumulated 222
K in total debt. Intervacc AB has a current ratio of 11.92, suggesting that it is
liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Intervacc until it has trouble settling it off, either with new capital or with free cash flow. So, Intervacc's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Intervacc AB sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Intervacc to invest in growth at high rates of return. When we think about Intervacc's use of debt, we should always consider it together with cash and equity.
Similar Executives
Intervacc AB , a biotechnology company, engages in the research and development of veterinary vaccines using recombinant proteins for animal health. The company has a collaboration with the Karolinska Institute. Intervacc operates under Biotechnology classification in Sweden and is traded on Stockholm Stock Exchange. It employs 12 people. Intervacc AB (IVACC) is traded on Stockholm Exchange in Sweden and employs 13 people.
Management Performance
Intervacc AB Leadership Team
Elected by the shareholders, the Intervacc's board of directors comprises two types of representatives: Intervacc inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Intervacc. The board's role is to monitor Intervacc's management team and ensure that shareholders' interests are well served. Intervacc's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Intervacc's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Newton Aguiar, Director | |
| JanIngmar Flock, CEO, Chief Scientific Officer, Director | |
| Bert Urlings, Director | |
| Andreas Andersson, Chief Executive Officer | |
| Stefan Stahl, Independent Director | |
| Rune Bergman, Chairman of the Board, Director Sales, Business Developer | |
| Marianne Hansson, Director | |
| Torben Joergensen, Director | |
| Jan Persson, Chief Financial Officer | |
| Olof Zachrisson, Director Clinical Development | |
| Andreas Johansson, Vice President - Supply Chain Management | |
| Bjorn Sjostrand, Chairman of the Board | |
| Patrik Hellberg, Chief Officer | |
| Andrew Waller, Chief Officer | |
| Bengt Guss, Independent Director | |
Intervacc Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Intervacc a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Additional Tools for Intervacc Stock Analysis
When running Intervacc's price analysis, check to
measure Intervacc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intervacc is operating at the current time. Most of Intervacc's value examination focuses on studying past and present price action to
predict the probability of Intervacc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Intervacc's price. Additionally, you may evaluate how the addition of Intervacc to your portfolios can decrease your overall portfolio volatility.